[1]CurrentPatentAssignee:MERCK&COINC-WO2015/35223,2015,A1Locationinpatent:Paragraph0948
[1]CurrentPatentAssignee:MERCK&COINC-WO2015/35223,2015,A1Locationinpatent:Paragraph0813
[2]CurrentPatentAssignee:MERCK&COINC-WO2016/145032,2016,A1Locationinpatent:Paragraph00507
[1]CurrentPatentAssignee:MERCK&COINC-WO2016/145236,2016,A1Locationinpatent:Paragraph0282-0283
[2]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2016/57242,2016,A1Locationinpatent:Paragraph0182;0183;0189
[3]CurrentPatentAssignee:MERCK&COINC-WO2016/145045,2016,A1Locationinpatent:Paragraph00462;00468
[4]CurrentPatentAssignee:MERCK&COINC-WO2019/191227,2019,A1Locationinpatent:Paragraph0253;0259
[5]CurrentPatentAssignee:CHINAPHARMACEUTICALUNIVERSITY-CN113651735,2021,ALocationinpatent:Paragraph0114-0120
[6]CurrentPatentAssignee:MERCK&COINC-US2018/140569,2018,A1Locationinpatent:Paragraph0814;0820
[1]Xu,Rui;Wang,Keshi;Rizzi,JamesP.;Huang,Heli;Grina,JonasA.;Schlachter,StephenT.;Wang,Bin;Wehn,PaulM.;Yang,Hanbiao;Dixon,DarrylD.;Czerwinski,RobertM.;Du,Xinlin;Ged,EmilyL.;Han,Guangzhou;Tan,Huiling;Wong,Tai;Xie,Shanhai;Josey,JohnA.;Wallace,EliM.[JournalofMedicinalChemistry,2019,vol.62,#15,p.6876-6893]
Title: Eli Wallace, Ph.D. PT2385: HIF-2α Antagonist for the Treatment of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016.
Title: Xie C, et al. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308.
Title: Wallace EM, et al. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500.
